Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Novel analytical methods to interpret large sequencing data from small sample sizes.

Lichou F, Orazio S, Dulucq S, Etienne G, Longy M, Hubert C, Groppi A, Monnereau A, Mahon FX, Turcq B.

Hum Genomics. 2019 Aug 30;13(1):41. doi: 10.1186/s40246-019-0235-1.

2.

Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state.

Tarfi S, Badaoui B, Freynet N, Morabito M, Lafosse J, Toma A, Etienne G, Micol JB, Sloma I, Fenaux P, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myelodysplasies (GFM).

Haematologica. 2019 Aug 14. pii: haematol.2019.219782. doi: 10.3324/haematol.2019.219782. [Epub ahead of print]

3.

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.

Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G; AdheRMC Investigators.

Br J Haematol. 2019 Aug 8. doi: 10.1111/bjh.16145. [Epub ahead of print]

PMID:
31394591
4.

[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, Réa D; pour la France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) et le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM).

Bull Cancer. 2019 Jul 26. pii: S0007-4551(19)30259-0. doi: 10.1016/j.bulcan.2019.05.011. [Epub ahead of print] Review. French.

PMID:
31353136
5.

Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.

Etienne G, Dulucq S, Huguet F, Schmitt A, Lascaux A, Hayette S, Fort MP, Sujobert P, Bijou F, Morisset S, Tavitian S, Bidet A, Turcq B, Robbesyn F, Chollet C, Belloc F, Durrieu F, Mahon FX, Nicolini FE.

Cancer Med. 2019 Sep;8(11):5173-5182. doi: 10.1002/cam4.2410. Epub 2019 Jul 27.

6.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Jul 10. doi: 10.1158/1078-0432.CCR-18-3373. [Epub ahead of print]

PMID:
31292142
7.

Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.

Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia.

Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9.

8.

The interfacial structure of nano- and micron-sized oil and water droplets stabilized with SDS and Span80.

Zdrali E, Etienne G, Smolentsev N, Amstad E, Roke S.

J Chem Phys. 2019 May 28;150(20):204704. doi: 10.1063/1.5083844.

PMID:
31153210
9.

Bioinspired Viscoelastic Capsules: Delivery Vehicles and Beyond.

Etienne G, Ong ILH, Amstad E.

Adv Mater. 2019 Jul;31(27):e1808233. doi: 10.1002/adma.201808233. Epub 2019 May 12.

PMID:
31081156
10.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.

Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.

PMID:
30798348
11.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

12.

Cross-talk between emulsion drops: how are hydrophilic reagents transported across oil phases?

Etienne G, Vian A, Biočanin M, Deplancke B, Amstad E.

Lab Chip. 2018 Dec 4;18(24):3903-3912. doi: 10.1039/c8lc01000e.

PMID:
30465575
13.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.

14.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
15.

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.

Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon FX, Dulucq S, Etienne G.

Exp Hematol. 2018 Aug;64:97-105.e4. doi: 10.1016/j.exphem.2018.05.003. Epub 2018 May 23.

PMID:
29800673
16.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

17.

Necrobiotic xanthogranuloma: a paraneoplastic skin lesion of haematological malignancies?

Omarjee L, Janin A, Etienne G, Bellou A, Stivalet O, Jaquinandi V, Mahe G.

Eur J Dermatol. 2018 Jun 1;28(3):384-386. doi: 10.1684/ejd.2018.3256. No abstract available.

PMID:
29619997
18.

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG.

Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.

19.

What is treatment free remission in chronic myeloid leukemia?

Rea D, Etienne G, Mahon FX.

Oncotarget. 2017 Dec 18;9(4):4279. doi: 10.18632/oncotarget.23398. eCollection 2018 Jan 12. No abstract available.

20.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
21.

Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane.

Chiaradia L, Lefebvre C, Parra J, Marcoux J, Burlet-Schiltz O, Etienne G, Tropis M, Daffé M.

Sci Rep. 2017 Oct 9;7(1):12807. doi: 10.1038/s41598-017-12718-4.

22.

No, treatment for CML should not continue indefinitely.

Etienne G, Mahon FX.

Clin Adv Hematol Oncol. 2017 Jun;15(6):489-494. No abstract available.

PMID:
28749910
23.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.

24.

Cultural Biases in Current Medical Practices with a Specific Attention to Orthopedic Surgery: a Review.

Etienne G, Pierce TP, Khlopas A, Chughtai M, Lavernia CJ, Vogelstein TY, Thomas CM, Modlin CS, Mont MA.

J Racial Ethn Health Disparities. 2018 Jun;5(3):563-569. doi: 10.1007/s40615-017-0400-y. Epub 2017 Jul 17.

PMID:
28718058
25.

Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.

Selimoglu-Buet D, Badaoui B, Benayoun E, Toma A, Fenaux P, Quesnel B, Etienne G, Braun T, Abermil N, Morabito M, Droin N, Solary E, Wagner-Ballon O; Groupe Francophone des Myélodysplasies.

Blood. 2017 Aug 10;130(6):832-835. doi: 10.1182/blood-2017-04-779579. Epub 2017 Jun 13. No abstract available.

PMID:
28611023
26.

Cell wall peptidolipids of Mycobacterium avium: from genetic prediction to exact structure of a nonribosomal peptide.

Bannantine JP, Etienne G, Laval F, Stabel JR, Lemassu A, Daffé M, Bayles DO, Ganneau C, Bonhomme F, Branger M, Cochard T, Bay S, Biet F.

Mol Microbiol. 2017 Aug;105(4):525-539. doi: 10.1111/mmi.13717. Epub 2017 Jun 15.

27.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

28.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
29.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

30.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

PMID:
27932374
31.

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence.

Boritsch EC, Frigui W, Cascioferro A, Malaga W, Etienne G, Laval F, Pawlik A, Le Chevalier F, Orgeur M, Ma L, Bouchier C, Stinear TP, Supply P, Majlessi L, Daffé M, Guilhot C, Brosch R.

Nat Microbiol. 2016 Jan 27;1:15019. doi: 10.1038/nmicrobiol.2015.19.

PMID:
27571976
32.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

33.

CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.

Nicolini FE, Alcazer V, Huguet F, Cony-Makhoul P, Heiblig M, Fort MP, Morisset S, Guerci-Bresler A, Soula V, Sobh M, d'Estaing SG, Daudin M, Etienne G.

Leuk Res. 2016 Sep;48:80-3. doi: 10.1016/j.leukres.2016.07.008. Epub 2016 Jul 22. No abstract available.

PMID:
27501271
34.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
35.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
36.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM.

Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.

37.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
38.

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.

Mansier O, Migeon M, Etienne G, Bidet A, Lippert E.

Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4. No abstract available.

PMID:
26727159
39.

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.

Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R.

Am J Hematol. 2016 Jun;91(4):366-70. doi: 10.1002/ajh.24278.

40.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
41.

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.

Fossard G, Blond E, Balsat M, Morisset S, Giraudier S, Escoffre-Barbe M, Labussière-Wallet H, Heiblig M, Bert A, Etienne M, Drai J, Sobh M, Redonnet-Vernhet I, Lega JC, Mahon FX, Etienne G, Nicolini FE.

Haematologica. 2016 Mar;101(3):e86-90. doi: 10.3324/haematol.2015.135103. Epub 2015 Dec 3. No abstract available.

42.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

43.

Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice.

Bakala N'Goma JC, Le Moigne V, Soismier N, Laencina L, Le Chevalier F, Roux AL, Poncin I, Serveau-Avesque C, Rottman M, Gaillard JL, Etienne G, Brosch R, Herrmann JL, Canaan S, Girard-Misguich F.

Infect Immun. 2015 Feb;83(2):780-91. doi: 10.1128/IAI.02032-14. Epub 2014 Dec 8.

44.

ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?

Etienne G, Dulucq S, Lascaux A, Schmitt A, Bidet A, Fort MP, Lippert E, Bureau C, Adiko D, Hayette S, Reiffers J, Nicolini FE, Mahon FX.

Am J Hematol. 2015 Jan;90(1):37-41. doi: 10.1002/ajh.23864. Epub 2014 Oct 25.

45.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

46.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119
47.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX.

Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20.

48.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036
49.

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

Dubois J, Etienne G, Laroche-Clary A, Lascaux A, Bidet A, Lippert E, Ait-ouferoukh S, Saada V, Micol JB, Bouabdallah K, Robert J.

Eur J Cancer. 2014 Jan;50(2):418-24. doi: 10.1016/j.ejca.2013.10.012. Epub 2013 Nov 14.

PMID:
24238921
50.

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

Mahon FX, Etienne G.

Clin Cancer Res. 2014 Jan 15;20(2):310-22. doi: 10.1158/1078-0432.CCR-13-1988. Epub 2013 Oct 28. Review.

Supplemental Content

Loading ...
Support Center